Amgen Inc. $AMGN Shares Purchased by King Luther Capital Management Corp

King Luther Capital Management Corp lifted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 0.3% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 509,158 shares of the medical research company’s stock after acquiring an additional 1,653 shares during the quarter. King Luther Capital Management Corp’s holdings in Amgen were worth $143,684,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in AMGN. Sequoia Financial Advisors LLC boosted its stake in Amgen by 2.3% in the third quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock valued at $45,334,000 after acquiring an additional 3,619 shares during the period. Atlantic Union Bankshares Corp boosted its position in Amgen by 165.0% during the 2nd quarter. Atlantic Union Bankshares Corp now owns 10,643 shares of the medical research company’s stock valued at $2,972,000 after purchasing an additional 6,627 shares during the period. Davis Capital Management bought a new stake in Amgen in the third quarter valued at $1,841,000. D.A. Davidson & CO. boosted its holdings in shares of Amgen by 2.6% during the third quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock valued at $68,590,000 after acquiring an additional 6,222 shares during the period. Finally, Global Wealth Management Investment Advisory Inc. grew its position in shares of Amgen by 56.2% during the third quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company’s stock worth $3,684,000 after acquiring an additional 4,699 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on AMGN. TD Cowen restated a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. Oppenheimer set a $400.00 price objective on Amgen and gave the stock an “outperform” rating in a report on Thursday, January 29th. Citigroup lifted their target price on Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. Leerink Partners increased their price target on Amgen from $305.00 to $355.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 4th. Finally, Cantor Fitzgerald raised their price target on Amgen from $315.00 to $350.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $351.83.

Amgen Trading Up 1.7%

Shares of Amgen stock opened at $379.73 on Thursday. The business has a fifty day simple moving average of $340.91 and a 200-day simple moving average of $315.28. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $385.12. The firm has a market cap of $204.70 billion, a price-to-earnings ratio of 26.69, a price-to-earnings-growth ratio of 3.82 and a beta of 0.46. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. The firm had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. Amgen’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period in the previous year, the business earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.7%. This is a positive change from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio (DPR) is presently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.